Northwest Biotherapeutics, Inc.
Northwest Biotherapeutics is developing DCVax® personalized dendritic cell-based therapeutic vaccines for solid tumors. The Company’s lead program is a 331-patient Phase III trial of DCVax®-L for Glioblastoma, the most aggressive and lethal form of brain cancer. This Phase III trial is completed and the trial data are being analyzed. The Company has also treated a variety of other solid tumors, with encouraging results, in compassionate use cases and other clinical trials.